Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Dirk Thomas
Observed name:
D. Thomas
Institution:
Bayer (Germany)
Observed institutions:
University Medical Center Groningen,
Bayer (Germany)
ORCID:
0000-0002-0061-1632
Observed ORCID:
0000-0002-0061-1632
OpenAlex ID:
A5001904850
Lacosamide
2007
·
Pamela Doty
, G. David Rudd
, et al.
·
Neurotherapeutics
·
168
PDF
First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa
2021
·
Dirk Thomas
, Friederike Kanefendt
, et al.
·
Journal of Thrombosis and Haemostasis
·
96
Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects
2020
·
Michael Boettcher
, Dirk Thomas
, et al.
·
European Journal of Clinical Pharmacology
·
81
PDF
BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics
2019
·
Dirk Thomas
, Kirstin Thelen
, et al.
·
Research and Practice in Thrombosis and Haemostasis
·
79
PDF
Metabolism and Pharmacokinetic Drug–Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies
2020
·
Michael Boettcher
, Michael Gerisch
, et al.
·
Clinical Pharmacokinetics
·
61
PDF
First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men
2022
·
Bettina Nowotny
, Dirk Thomas
, et al.
·
Journal of Thrombosis and Haemostasis
·
30
Pharmacokinetic Interaction of Riociguat with Ketoconazole, Clarithromycin, and Midazolam
2016
·
Corina Becker
, Reiner Frey
, et al.
·
Pulmonary Circulation
·
29
The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial
2024
·
Ron T Gansevoort
, David C Wheeler
, et al.
·
Nephrology Dialysis Transplantation
·
26
PDF
640 Low Potential for Drug‐drug‐interaction of Lacosamide
2006
·
D. Thomas
, U. Scharfenecker
, et al.
·
European Journal of Pain
·
22
New Generation of sGC Stimulators: Discovery of Imidazo[1,2-a]pyridine Carboxamide BAY 1165747 (BAY-747), a Long-Acting Soluble Guanylate Cyclase Stimulator for the Treatment of Resistant Hypertension
2023
·
Alexandros Vakalopoulos
, Frank Wunder
, et al.
·
Journal of Medicinal Chemistry
·
19
196 Low Potential for Drug—drug‐interaction of Lacosamide
2007
·
D. Thomas
, U. Scharfenecker
, et al.
·
European Journal of Pain
·
11
Pharmacokinetic interaction of ketoconazole, clarithromycin, and midazolam with riociguat
2013
·
Corina Becker
, Reiner Frey
, et al.
·
BMC Pharmacology and Toxicology
·
9
PDF
(752)
2007
·
D. Thomas
, U. Scharfenecker
, et al.
·
Journal of Pain
·
5
PDF
195 Lacosamide Demonstrates No Potential for Qtc‐prolongation
2007
·
D. Thomas
, J. Zisowsky
, et al.
·
European Journal of Pain
·
4
The sGC activator runcaciguat is associated with a strong reduction in albuminuria and good tolerability in CKD patients with or without an SGLT2 inhibitor. Results of the CONCORD study
2024
·
Ron T. Gansevoort
, David C. Wheeler
, et al.
·
2
PDF
Investigation of bioequivalence, safety, and tolerability of a fixed-dose combination of nifedipine GITS and candesartan compared with the corresponding loose-dose combination under fed conditions
2019
·
Dirk Thomas
, Yuwang Liu
, et al.
·
International Journal of Clinical Pharmacology and Therapeutics
·
1
Pharmacokinetic (PK) interaction of ketoconazole (KC), clarithromycin (CM) and midazolam (MZ) with riociguat
2013
·
Corina Becker
, Reiner Frey
, et al.
·
European Respiratory Journal
·
1
Investigation of bioequivalence of a new fixed-dose combination of nifedipine and candesartan with the corresponding loose combination as well as the drug-drug interaction potential between both drugs under fasting conditions
2013
·
Erich Brendel
, Boris Weimann
, et al.
·
International Journal of Clinical Pharmacology and Therapeutics
·
1
641 Lacosamide Has No Potential for Interaction With Metformin
2006
·
B. Schiltmeyer
, D. Thomas
, et al.
·
European Journal of Pain
·
1
Design of SIRIUS: a randomized placebo-controlled Phase II study of inclocibart, an antibody against α2-antiplasmin, for proximal deep vein thrombosis
2026
·
Jan Beyer-Westendorf
, Dirk Thomas
, et al.
·
TH Open
Show more works
View as search
Works count:
20
Citation count:
646
H-index:
11
I10-index:
11
Year
Topic
Type
